ABSTRACT Sera of 106 normal adult men were tested for antibodies reacting with cell surface antigens of three established lines of cultured malignant melanoma. Positive reactions with a protein A assay for IgG antibodies were extremely rare (1-2%). The frequency of positive reactions with assays for IgM antibodies was higher 5-15% in immune adherence assays and 55-82% in anti-C3 mixed hemadsorption assays. After low-titered sera and sera reacting with fetal calf serum components, conventional alloantigens, and widely distributed class 3 antigens were excluded, sera from seven individuals (one with IgG antibody and six with IgM antibodies) were selected for detailed analysis. The serum containing the IgG antibody came from a healthy 65-year-old Caucasian man; titers of antibody in his serum ranged from <1/10 to 1/40,000 in tests with different melanoma cell lines. This IgG antibody identifies a differentiation antigen of melanocytes, provisionally designated Mel 1, that distinguishes two classes of melanomas: 22 melanoma cell lines typed Mel 1+ and 17 typed Mel 1-. Mel 1 is expressed by fetal fibroblasts but not adult fibroblasts and can be found on a proportion of cultured epithelial cancer cell lines (5 out of 23) but not on glioma or B-cell lines. The melanoma antigens detected by the naturally occurring IgM antibodies are serologically unrelated to Mel 1 but, like Mel 1, appear to be differentiation antigens that distinguish subsets of melanoma. These IgM antibodies detect antigens that are identical or closely related to the AH antigen, a melanoma surface antigen that was initially defined by autologous antibody in a patient with melanoma. In view of the immunogenicity of both Mel 1 and the AH antigens in humans and their occurrence on more than 50% of melanomas, it remains to be seen whether antibody to these antigens can be elicited by specific vaccination of seronegative melanoma patients and whether this will have an influence on the clinical course of the disease.
ABSTRACT Sera of 106 normal adult men were tested for antibodies reacting with cell surface antigens of three established lines of cultured malignant melanoma. Positive reactions with a protein A assay for IgG antibodies were extremely rare (1-2%). The frequency of positive reactions with assays for IgM antibodies was higher 5-15% in immune adherence assays and 55-82% in anti-C3 mixed hemadsorption assays. After low-titered sera and sera reacting with fetal calf serum components, conventional alloantigens, and widely distributed class 3 antigens were excluded, sera from seven individuals (one with IgG antibody and six with IgM antibodies) were selected for detailed analysis. The serum containing the IgG antibody came from a healthy 65-year-old Caucasian man; titers of antibody in his serum ranged from <1/10 to 1/40,000 in tests with different melanoma cell lines. This IgG antibody identifies a differentiation antigen of melanocytes, provisionally designated Mel 1, that distinguishes two classes of melanomas: 22 melanoma cell lines typed Mel 1+ and 17 typed Mel 1-. Mel 1 is expressed by fetal fibroblasts but not adult fibroblasts and can be found on a proportion of cultured epithelial cancer cell lines (5 out of 23) but not on glioma or B-cell lines. The melanoma antigens detected by the naturally occurring IgM antibodies are serologically unrelated to Mel 1 but, like Mel 1, appear to be differentiation antigens that distinguish subsets of melanoma. These IgM antibodies detect antigens that are identical or closely related to the AH antigen, a melanoma surface antigen that was initially defined by autologous antibody in a patient with melanoma. In view of the immunogenicity of both Mel 1 and the AH antigens in humans and their occurrence on more than 50% of melanomas, it remains to be seen whether antibody to these antigens can be elicited by specific vaccination of seronegative melanoma patients and whether this will have an influence on the clinical course of the disease.
Despite considerable attention and effort, it remains unclear whether immunological factors play any role in the pathogenesis of malignant melanoma. The major problem in resolving this issue centers on the question of whether melanoma-specific antigens exist and whether patients recognize these antigens during the course of their disease. Although a vast literature has accumulated on the subject of humoral and cellular immune reactions to melanoma, little in the way of critical or convincing evidence for melanoma-specific antigens has been forthcoming. What has been lacking in most studies dealing with this question is proof that the reactions observed were not due to immunity directed against HLA alloantigens, major or minor blood group antigens, or other classes of alloantigenic differentiation antigens. To eliminate the need to consider interference by alloantibodies, we turned several years ago to an analysis of the immune reactivity of patients directed against cell surface antigens of their own tumors. The approach that evolved in these studies, which we have termed autologous typing, has now been applied to the study of several human tumor types-melanoma (1-3), astrocytoma (4), leukemia, (5), and renal cancer (6) (2) , the serologically related AJ astrocytoma antigen (4) , and the AX and AG antigens of renal cancer (6) . AH The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact. (8) . Melanocytes were cultured from postmortem specimens of adult human choroid. Cultures were maintained in Eagle's minimal essential medium supplemented with 2 mM glutamine, 1% nonessential amino acids, 100 Ag of penicillin per ml, 1 Ag of streptomycin per ml, and 10% (vol/vol) fetal bovine serum. In order to remove heterologous fetal bovine serum components, melanoma cells were cultured in screened 10% (vol/vol) human sera from AB blood-type donors for at least 6 weeks (generally three subcultures).
Cultures were regularly tested for mycoplasma, fungi, and bacteria, and contaminated cultures were discarded.
Sera. Sera were collected from healthy, nontransfused men and stored at -70'C. Age of the serum donors ranged from 19 to 65 years. Serological Procedures. The protein A hemadsorption (PA), immune adherence (IA) and anti-C3 mixed hemadsorption (C3-MHA) assays were performed as described (2) (3) (4) 6 Table 1 . Reactivity was detected most frequently in C3-MHA assays, considerably less frequently in IA assays, and only rarely in PA assays. Naturally occurring antibodies to A or B blood-group antigens did not contribute to these results; the target cells do not express A or B antigens and there was no association between serum reactivity and ABO type of the serum donor.
Tests with Sera Reactive in PA Assays. Sera from 2 of the 106 normal men (NS 74 and NS 124) had measurable antibody to melanoma surface antigens detected by PA assays. NS 74 reacted with the three melanoma target cell lines at titers of 1/128-1/256. Antibody in NS 74 was directed against fetal calf components adsorbed to the surface of the target cells; the reactivity of NS 74 could be absorbed by fetal calf serum, and NS 74 had no reactivity with melanoma target cells grown in human serum rather than in fetal calf serum.
NS 124 reacted with two of the three melanoma cell lines with a titer of 1/40,000 on SK-MEL-29 cells, 1/640 on SK-MEL-28 cells, and <1/8 on SK-MEL-13 (Fig. 1) . These titers remained unchanged in tests with target cells cultured in human serum. Parallel reactivity was demonstrable by using another assay for IgG antibody (anti-human IgG indicator cells), whereas NS 124 had no reactivity in the two IgM detection systems (IA or C3-MHA assays). Results with immunoglobulin fractions of NS 124 were consistent with the conclusion that the melanoma reactivity of NS 124 was due to antibody belonging to the IgG class.
Analysis of Melanoma Reactivity of NS 124. The donor of NS 124 is a retired 65-year-old Caucasian man of Irish extraction who has always enjoyed good health and has no allergies, recent immunizations, or family history of cancer. No suspicious skin or soft tissue lesions were evident on physical examination. Titers of antibody reactive with SK-MEL-28 and SK-MEL-29 remained constant in three serum specimens taken from this individual over an 18-month period. Immunoglobulin levels in NS 124 were normal (IgG, 970 mg/100 ml; IgM, 200 mg/100 ml; and IgA, 200 mg/100 ml) and serum immunoelectrophoresis revealed no abnormalities. 
lower curves), whereas four other cell types (including another melanoma line, SK-MEL-37, and a Bcell line from the donor of SK-MEL-29) did not absorb reactivity (upper curves). Table 2 summarizes the results of the absorption tests that have been done. Twenty-two of 39 melanoma cell lines (56%) absorbed reactivity from NS 124, as did cultured fetal fibroblasts (derived from 16-to 20-week-old fetuses) and certain epithelial cancer lines. Adult (Table 3) . Cell lines that absorbed NS 124 reactivity for SK-MEL-29 were also positive in direct PA tests. Conversely, cell lines that had no absorbing capacity failed to react in direct tests. Furthermore, antigen expression, as indicated by the titer of NS 124 in direct tests, correlated with the absorption capacity of cell lines. Cell lines with high antigen expression (1/640-1/40,000) showed complete absorption, whereas lines with lower antigen expression showed partial absorption.
Reactions of NS 124 with Cultured Melanocytes. Shortterm cultures of melanocytes from adult choroid reacted with NS 124 in PA assays. (Tests with sera from 12 other normal individuals were negative.) The titers of NS 124 in tests with melanocytes from five individuals (6-10 days after in vitro culture) ranged from 1/100 to 1/200. Fibroblasts and epithelial cells, which could be distinguished in these cultures, were not reactive with NS 124. To determine the relationship between the antigen detected on melanocytes and that on melanoma Immunology: Houghton et al.
activity of normal human sera with melanoma surface antigens. To investigate this point further, sera from women, older individuals, and individuals of different ethnic and geographic background must be tested with these assays and with other serological tests to detect IgG antibody. Until such a detailed picture of the reactivity of normal individuals to surface antigens of melanoma has been developed it will be difficult to place in perspective the serological findings in patients with melanoma, in individuals with other types of pigment disorders, or in members of families with a high melanoma incidence.
The general method for determining the specificity of melanoma antibodies found in normal individuals follows procedures developed in our study of autologous reactivity to melanoma cells in melanoma patients (autologous typing). The following comments summarize some of the salient points.
(i) Antibodies to components in fetal calf serum are not uncommon in human sera, and because these fetal calf components can adsorb to the surface of cells, sera containing such antibodies will give positive reactions with cells grown in fetal calf serum. As a rule, antibody to these antigens can be eliminated by absorption with fetal calf serum. However, a critical test to rule out reactivity due to fetal calf components is to grow target cells in human sera for several passages and see whether the reactivity of positive sera persists.
(Ui) Alloantibodies to conventional HLA products can be expected in pregnant or parous women and in transfused individuals, and these can interfere with the detection of antibodies to other classes of surface antigens. For this reason, the sera in this initial survey came from normal men with no history of blood transfusion. Methods are available, however, to rule out reactions due to HLA antibodies, permitting the analysis of complex sera containing these antibodies. B-cell lines kransformed by Epstein-Barr virus) and lines of normal fi-*broblasts can be established from patients whose melanoma cells are used as target cells in tests for natural antibody. If reactivity for melanoma cells is not removed by autologous B cells or fibroblasts, the presumption is that alloantibodies to HLA products are not involved. B cells have an advantage over fibroblasts in this regard because B cells express HLA-D products and these antigens are also expressed by melanoma cells (9, 10) . Insofar as it has been tested, melanoma cells have not been found to express A or B blood-group antigens. With other types of cancer, particularly epithelial cancers that do express these antigens, absorptions with A and B erythrocytes are necessary to evaluate the contributions of naturally occurring antibodies to these antigens.
(iii) In addition to antibodies to fetal calf components, HLA products, and blood-group antigens, human sera contain antibodies that react with antigens that are widespread on cultured cells. These antigens, which we have referred to as class 3 antigens in autologous typing (3), are diverse and complex and have not been studied in detail. Nonetheless, antibodies to most class 3 antigens can be easily removed by absorption with cultured cells, both normal and malignant, of autologous, allogeneic, or heterologous origin.
Seven of the 14 sera that were analyzed in detail have reactivity that cannot be ascribed to antibodies against fetal calf components, HLA antibodies, or widely represented class 3 antigens. The antigen detected by IgG antibody in the sera of one individual has the characteristics of a melanocyte differentiation antigen, and for this reason we have provisionally designated this antigen Mel 1. It is found on normal melanocytes cultured from the choroid, but not on cultured adult fibroblasts, B cells, or T cells or on peripheral blood cells. Of the 39 lines of melanoma tested, 22 expressed Mel 1 and 17 did not, the latter presumably being derived from progenitor cells in the melanoblast -melanocyte lineage prior to the stage at which this antigen is normally expressed. An alternative explanation for this finding is that two separate pathways for pigment cell development are involved-e.g., melanocytic and nevocytic (11)-and that only those cells differentiating along one of the two pathways express Mel 1. Whatever the explanation, the demonstration of two clearly defined melanoma subsets provides the opportunity to see whether this difference correlates with biological or clinical features of melanoma. Another characteristic of this antigenic system is its presence on fibroblasts of fetal origin but not on adult fibroblasts. Once again, this could indicate derivation from cells at different phases in the same cellular lineage or derivation from two distinct lineages. Another possibility to account for the Mel 1-phenotype of adult fibroblasts would be phenotypic repression of a fetal trait in certain adult cells.
Analysis of the IgM antibodies detected by C3-MHA assays indicates that the antigens identified by these antibodies are unrelated to Mel 1. Detailed study of one of these IgM antibodies shows that it detects an antigen with the same distribution as the AH antigen of melanoma (2) and the serologically related AJ antigen of astrocytomas (4) . A similar pattern of reactivity has been found with five other naturally occurring IgM antibodies. Thus, the AH/AJ antigen represents a class of differentiation antigens that has the potential for autoantigenicity in normal individuals and in patients with cancer. (The possibility that natural antibody to AH/AJ antigen arises as a consequence of infection with an oncogenic virus involved in the etiology of melanoma and other AH/AJ+ tumors appears unlikely, but cannot be excluded by present evidence.) Because the melanoma patient whose serum originally defined the AH system has had an unusually favorable clinical course, the possibility exists that immunity to AH antigen is in some way protective. Attempts to raise AH antibody in melanoma patients by deliberate immunization with AH+ cells are underway to evaluate this possibility.
